[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356440-105":59,"doc-detail-356440-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","real-world-analysis-of-interstitial-lung-diseasepneumonitis-in-japanese-patients-with-breast-cancer-receiving-trastuzumab-deruxtecan","Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan","","Postmarketing surveillance investigated incidence and risk factors of interstitial lung disease (ILD) and pneumonitis in Japanese patients with HER2-positive unresectable or recurrent breast cancer receiving trastuzumab deruxtecan (T-DXd). Included patients initiated T-DXd in Japan from May 25, 2020 to November 30, 2021. Primary outcome was adjudicated drug-related ILD; associations were evaluated using a Cox proportional hazards model. Drug-related ILD incidence was 16.1% (any grade), 3.0% (grade ≥3), and 1.0% (grade 5), with baseline factors linked to increased risk.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-analysis-of-interstitial-lung-diseasepneumonitis-in-japanese-patients-with-breast-cancer-receiving-trastuzumab-deruxtecan/356440/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-analysis-of-interstitial-lung-diseasepneumonitis-in-japanese-patients-with-breast-cancer-receiving-trastuzumab-deruxtecan/356440.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary goal of this postmarketing surveillance study?","Question",{"text":112,"@type":113},"To investigate the incidence of adjudicated drug-related interstitial lung disease (ILD) in Japanese patients with breast cancer receiving trastuzumab deruxtecan (T-DXd), and to identify related factors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who was included in the study?",{"text":117,"@type":113},"All patients with HER2-positive unresectable or recurrent breast cancer who initiated T-DXd in Japan between May 25, 2020 and November 30, 2021 were included.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the observed incidences and severity levels of drug-related ILD?",{"text":121,"@type":113},"Among 1,731 patients, adjudicated drug-related ILD occurred in 16.1% (any grade), 3.0% (grade ≥3), and 1.0% (grade 5).",{"name":123,"@type":110,"acceptedAnswer":124},"Which baseline factors were associated with increased risk of drug-related ILD?",{"text":125,"@type":113},"Male sex, higher body mass index (≥ median 21.3 kg/m2), history/comorbidity of ILD, and impaired renal function were identified as baseline factors potentially associated with increased risk.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},356440,1790151114,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Breast Cancer (2026) 33:346–358  \n[https://doi.org/10.1007/s12282-025-01814-3](https://doi.org/10.1007/s12282-025-01814-3)  \nORIGINAL ARTICLE  \nReal-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan  \nJunji Tsurutani1 · Kengo Noguchi2 · Ayumi Tanabe3  \nReceived: 29 August 2025 / Accepted: 6 December 2025 / Published online: 31 January 2026 © The Author(s) 2026  \nAbstract  \nBackground While trastuzumab deruxtecan (T-DXd) shows efficacy in various cancers, interstitial lung disease (ILD) and pneumonitis are significant risks associated with its use. Understanding these risks is crucial for effective management and safe administration ofT-DXd. Therefore, we conducted a postmarketing surveillance study in Japan to investigate the incidence ofILD and related factors.  \nMethods All patients with human epidermal growth factor receptor 2-positive unresectable or recurrent breast cancer who initiated T-DXd in Japan between May 25, 2020, and November 30, 2021, were included. The primary outcome was the incidence of adjudicated drug-related ILD, and its associated factors were investigated using a Cox proportional hazards model. Results The safety analysis set included 1,731 patients with a median (range) age of 60 (27–87) years. The median (range) duration ofT-DXd treatment was 9.4 (0.7–17.9) months. A total of 24 (1.4%) and 11 (0.6%) patients had ILD as a medical history and comorbidity, respectively. The incidence of any Grade, Grade ≥ 3, and Grade 5 adjudicated drug-related ILD was 16.1%, 3.0%, and 1.0%, respectively. The median (range) time from the first T-DXd treatment to the first onset ofILD was 5.1 (0 .5–17.3) months. Male sex, higher body mass index (≥ median [21 .3 kg/m2]), history/comorbidity ofILD, and impaired renal function were identified as baseline factors potentially associated with an increased risk of drug-related ILD. Conclusions The incidence of adjudicated drug-related ILD in the real-world setting was similar to that observed in clinical trials.  \nKeywords Breast cancer · Interstitial lung disease · Postmarketing surveillance · Real world · Trastuzumab deruxtecan  \nIntroduction  \nIn 2022, breast cancer was the most common cancer in Japanese women, constituting 21.6% of all cancers and ranking as the sixth leading cause of death overall (4.1% of all cancer-related deaths) [1] . Human epidermal growth  \n􀀍 Junji Tsurutani [tsurutaj@med.showa-u.ac.jp](tsurutaj@med.showa-u.ac.jp)  \n1 Advanced Cancer Translational Research Institute, Showa Medical University, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan  \n2 Pharmacoepidemiology & PMS Department, Daiichi Sankyo Co., Ltd., Tokyo 103-8426, Japan  \n3 Data Intelligence Department, Daiichi Sankyo Co., Ltd., Tokyo 140-8710, Japan  \nfactor receptor 2 (HER2) overexpression or amplification in patients with breast cancer is associated with poor prognosis and increased risk of disease recurrence and mortality compared with patients whose tumors do not overexpress HER2 [2, 3] . In the Japanese National Clinical Database (N= 95,620), 11.4% of patients had HER2-positive breast cancer in 2018 [4] . The introduction of the anti-HER2 monoclonal antibody trastuzumab revolutionized the management of HER2-positive breast cancer, improving the prognosis and survival of patients [5] . Subsequently, several drugs targeting the HER2 pathway have been approved for the treatment of HER2-positive breast cancer in Japan, including trastuzumab deruxtecan (T-DXd), which was approved in March 2020 to treat unresectable or recurrent HER2-positive breast cancer that has progressed after cancer chemotherapy [6] . The DESTINY-Breast01 trial showed an overall response rate (ORR) of approximately  \n61.0% in patients with metastatic breast cancer who had received a median of 6 prior treatments [7] . In subsequent clinical trials, T-DXd demonstrated a significantly longer progression-free survival (PFS) than physicians’","cbCaivLbMRdSNq4N","https://ap.wps.com/l/cbCaivLbMRdSNq4N","pdf",1457244,13,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the primary goal of this postmarketing surveillance study?\",\"answer\":\"To investigate the incidence of adjudicated drug-related interstitial lung disease (ILD) in Japanese patients with breast cancer receiving trastuzumab deruxtecan (T-DXd), and to identify related factors.\"},{\"question\":\"Who was included in the study?\",\"answer\":\"All patients with HER2-positive unresectable or recurrent breast cancer who initiated T-DXd in Japan between May 25, 2020 and November 30, 2021 were included.\"},{\"question\":\"What were the observed incidences and severity levels of drug-related ILD?\",\"answer\":\"Among 1,731 patients, adjudicated drug-related ILD occurred in 16.1% (any grade), 3.0% (grade ≥3), and 1.0% (grade 5).\"},{\"question\":\"Which baseline factors were associated with increased risk of drug-related ILD?\",\"answer\":\"Male sex, higher body mass index (≥ median 21.3 kg/m2), history/comorbidity of ILD, and impaired renal function were identified as baseline factors potentially associated with increased risk.\"}]","Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan | PDF",1790125341,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c1685ada8422bb5e62e8c81276d2ad3.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27a39a46fb19a932d8db01bb031989e5.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/662f198f233ee834191c701e1a8106d1.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a622866c1b0e1bd2c39899c2e366988.webp",980,1301]